Eloxx Pharmaceuticals Inc

NASDAQ:ELOX  
0.17
+0.02 (+12.48%)
Products, Regulatory

Eloxx Pharmaceuticals Reports Topline Results From Phase 2 Combination Clinical Trial Of ELX-02 In Class 1 Cystic Fibrosis (CF) Patients

Published: 09/14/2022 20:19 GMT
Eloxx Pharmaceuticals Inc (ELOX) - Eloxx Pharmaceuticals Reports Topline Results From Phase 2 Combination Clinical Trial of Elx-02 in Class 1 Cystic Fibrosis (cf) Patients.
Eloxx Pharmaceuticals Inc - Elx-02 Was Well Tolerated With No Drug-related Serious Adverse Events Observed.
Eloxx - Combination of Subcutaneous Elx-02 With Ivacaftor Did Not Achieve Statistical Significance for Efficacy Endpoints in Phase 2 Study in Class 1 Cf.
Eloxx Pharmaceuticals Inc - Evidence of Activity for Elx-02 Observed; Efficacy Signal Potentially Confounded by Variability Due to Low Drug Exposure.